Biotech Stocks Reviews
- Jounce Rallies At JP Morgan Conference As Investors Pick Up On ILT4 Story
Fri, Jan 15
Jounce is up about 20% this week after presenting at JP Morgan and announcing the first patient was · more » - Magenta’s 2021 Catalysts May Provide Proof of Concept for Transplant Mobilization & Conditioning
Fri, Jan 15
We wrote about Magenta (MGTA) back in the summer of 2020 when the stock was in the $9 range. The thesis · more » - Essa Lands Janssen as mCRPC Partner After Pfizer Led Deal
Thu, Jan 14
Essa (EPIX)announceda collaboration with Janssen (Johnson Johnson’s biotech arm) yesterday morning to · more » - Funds Make $100M Bet That Affimed Becomes a Main NK Player
Wed, Jan 13
Affimedannounceda $100M offering this morning. 16.7M shares @ $6/share. On Monday, theyannounceda $30M · more » - Getting Ahead of Oncology’s Next Target With This Company
Tue, Jan 12
Jounce is developing an ILT4 antibody that can unleash the cancer killing effect of macrophages. · more » - Names to Watch in 2021
Tue, Jan 5
The prior email covered near-term 2021 catalysts forDCTH,CNCEandEPIX(HERE). The note below includes · more » - Essa’s Strong Run to End 2020 Show High Expectations for Upcoming Phase 1
Mon, Dec 28
Essa Pharma (EPIX) has been on a tear in the last week. Shares are up 35% from the $8 range to now · more » - 3 Catalyst Names for Early 2021
Mon, Dec 28
Delcath, Concert and Essa are 3 holdings with catalysts in early 2021. Below is a look at these · more » - Aerpio Tries to Hide Phase 2 Glaucoma Data Flop
Mon, Dec 14
Aerpio (ARPO)announcedPhase 2 topline glaucoma data last Friday after the market closed. The study · more »